| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/11/2000 | US6087167 Promoting neuron survival or neurite outgrowth by contacting neurons with an amount of an eck receptor binding protein of specific amino acid sequence |
| 07/11/2000 | US6087150 Interleukin-1 β converting enzyme like apoptosis protease-3 and 4 |
| 07/11/2000 | US6087144 Mammalian enzymatic protein receptor; for the activation of cell differentiation and propagation; for screening modulators or receptor activity |
| 07/11/2000 | US6087142 Valyl tRNA synthetase from streptococcus pneumoniae |
| 07/11/2000 | US6087117 Murine immunoglobulin which binds to mamalian tumor protein; for genetic testing of cancer senesitivity, diagnosis, and treatment |
| 07/11/2000 | US6087110 Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| 07/11/2000 | US6087105 Nucleotide sequences coding a protein associated with adherence and infection of bacterial parasite; for detection of modulators of bacterial adhesion |
| 07/11/2000 | US6086902 Recombinant bovine herpesvirus type 1 vaccines |
| 07/11/2000 | US6086901 Imunological adjuvants and antigen entrapment |
| 07/11/2000 | US6086899 Ethylene oxide-propylene oxide copolymer |
| 07/11/2000 | US6086898 Administering listeria adjuvants and antigens for immunology |
| 07/11/2000 | US6086897 Isolation peptide from a protein allergen of dermatophagoide |
| 07/11/2000 | US6086896 Antigenic iron repressible protein from N. meningitidis related to the hemolysin family of toxins |
| 07/11/2000 | US6086895 Treatment with proteins and polypeptides |
| 07/11/2000 | US6086894 Recombinant vaccine for diseases caused by encapsulated organisms |
| 07/11/2000 | US6086893 Helicobacter lactoferrin receptor |
| 07/11/2000 | US6086892 Poultry vaccine |
| 07/11/2000 | US6086891 Plasmids |
| 07/11/2000 | US6086881 Spatially aligned conjugated composition having a thioether bond linkage |
| 07/11/2000 | US6086878 By administering a gastrointestinal neuromodulator antibody, such as antibodies to bombesin, cholecystokinin, gastrin, somatostatin, and neuropeptide y; for egg or milk-producing animals |
| 07/11/2000 | US6086877 Therapeutic agent for rheumatic disease |
| 07/11/2000 | US6086876 Suppressing interleukin-12 (il-12) production in a human by administering a ligand that binds the complement receptor protein cd46, the ligand suspended in a carrier and binding suppresses il-12 production; treating autoimmune diseases |
| 07/11/2000 | US6086875 Receptor specific transepithelial transport of immunogens |
| 07/11/2000 | US6086874 Kit comprising an interleukin-6 (il-6) antagonist such as antibody to il-6, antibody to il-6 receptor, and antibody to gp130 protein, an antitumor agent such as cisplatin, and a carrier; antagonist and antitumor agent not physically bonded |
| 07/11/2000 | US6086873 Irradiating an antibody with ultraviolet light to expose a reactive sulfhydryl of the antibody without changing its biological function, administering to a host to generate a greater immune response than against the native antibody |
| 07/11/2000 | US6086867 By contacting the cell with a soluble polypeptide comprising the amino acid sequence of the extracellular domain of the transforming growth factor-beta (tgf-b) type iii receptor protein or mammalian dna encoding it |
| 07/11/2000 | CA2082948C Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding |
| 07/11/2000 | CA2079912C Hepatitis c virus epitopes |
| 07/11/2000 | CA1341050C Neurite growth regulatory factors |
| 07/11/2000 | CA1341048C Method and compositions for making acsf and acsf antagonists |
| 07/06/2000 | WO2000039589A1 Treatment and diagnosis of cancer using inositolphosphoglycans antagonists |
| 07/06/2000 | WO2000039588A1 Detection of preactivated phagocytes |
| 07/06/2000 | WO2000039400A1 System for predicting compaction performance |
| 07/06/2000 | WO2000039310A1 Rubredoxin fusion proteins, protein expression system and methods |
| 07/06/2000 | WO2000039304A2 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 07/06/2000 | WO2000039303A2 Modified hiv env polypeptides |
| 07/06/2000 | WO2000039302A2 Improved expression of hiv polypeptides and production of virus-like particles |
| 07/06/2000 | WO2000039301A2 Methods for using mycobacterium tuberculosis molecules as immunological adjuvants |
| 07/06/2000 | WO2000039299A2 Streptococcus antigens |
| 07/06/2000 | WO2000039298A1 Chimeric gene encoding the antigenic determinants of four proteins of l. infantum |
| 07/06/2000 | WO2000039287A2 A. fumigatus acetyl coenzyme-a carboxylase genes and polypeptides and uses thereof |
| 07/06/2000 | WO2000039283A1 Use of cd40 engagement to alter t cell receptor usage |
| 07/06/2000 | WO2000039160A2 Caspase-8 interacting proteins |
| 07/06/2000 | WO2000039159A1 Superantigens |
| 07/06/2000 | WO2000039158A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 07/06/2000 | WO2000039157A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 07/06/2000 | WO2000039154A2 Peptides of the at1 receptor and their use for preeclampsia and malign hypertension |
| 07/06/2000 | WO2000039145A1 Targeted gene transfer using g protein coupled receptors |
| 07/06/2000 | WO2000039136A2 Human brainiac-5 |
| 07/06/2000 | WO2000038786A2 Use of cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | WO2000038743A1 Removal of biological contaminants |
| 07/06/2000 | WO2000038730A2 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia |
| 07/06/2000 | WO2000038719A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia |
| 07/06/2000 | WO2000038718A2 Use of matrix metalloproteinase inhibitor together with an antineoplastic agents, optionally also together with radiation, in the treatment of neoplasia |
| 07/06/2000 | WO2000038717A2 Use of a matrix metalloproteinase inhibitor and radiation as a combined treatment of neoplasia |
| 07/06/2000 | WO2000038715A2 Use of an integrin antagonist and radiation in the treatment of neoplasia |
| 07/06/2000 | WO2000038713A1 Agonists or antagonists of cutaneous t cell-attracting chemokine (ctack) or vasoactive intestinal contractor (vic) chemokines |
| 07/06/2000 | WO2000038712A2 Method for producing autogenous vaccines for treating chlamydial infections in mammals and humans |
| 07/06/2000 | WO2000038711A2 Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
| 07/06/2000 | WO2000038710A2 Dual hapten modified tumor cells and tumor polypeptides and methods of treating cancer |
| 07/06/2000 | WO2000038706A2 Methods for treating cancer and for mediating chemotaxis of dendritic cells |
| 07/06/2000 | WO2000038665A2 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | WO2000038515A1 Peptide mimics useful for treating disease |
| 07/06/2000 | WO2000024428A3 Cationic lipid-mediated enhancement of nucleic acid immunization of cats |
| 07/06/2000 | WO2000020612A3 Therapeutically active proteins in plants |
| 07/06/2000 | WO2000020584A3 Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6 |
| 07/06/2000 | WO2000018430A3 Live virus vaccines to protect primates from hiv-1 infection and disease |
| 07/06/2000 | WO2000018429A3 Vaccine based on attenuated $i(haemophilus somnus) |
| 07/06/2000 | WO2000018387A3 Antibiotic compositions for treatment of the eye, ear and nose |
| 07/06/2000 | WO2000017222A8 31 human secreted proteins |
| 07/06/2000 | WO2000016061B1 Method for diagnosing the active stage of a cytomegalovirus infection in human substrates |
| 07/06/2000 | WO2000014222A3 Gabab receptor subtypes gabab-r1c and gabab-r2 and heterodimers thereof |
| 07/06/2000 | WO2000013703A3 Methods of treating hypertension and compositions for use therein |
| 07/06/2000 | WO2000000616A3 Marburg virus vaccines |
| 07/06/2000 | WO1999061600A9 A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 07/06/2000 | WO1999054447A3 Human nucleic acid sequences of bladder tumour tissue |
| 07/06/2000 | WO1999046375A3 Human nucleic acid sequences from prostate tissue |
| 07/06/2000 | WO1999040119A9 Monoclonal antibody which recognizes the oligosaccharide n-glycolylated-galactose-glucose sialic acid in malignant tumors, and composition containing it |
| 07/06/2000 | CA2621097A1 Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
| 07/06/2000 | CA2363999A1 Peptides of the at1 receptor and their use for preeclampsia and malign hypertension |
| 07/06/2000 | CA2358385A1 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 07/06/2000 | CA2356929A1 Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combonation therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356894A1 Removal of biological contaminants |
| 07/06/2000 | CA2356755A1 Superantigens |
| 07/06/2000 | CA2356748A1 Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356669A1 Methods for using mycobacterium tuberculosis molecules as immunological adjuvants |
| 07/06/2000 | CA2356661A1 Agonists or antagonists of cutaneous t cell-attracting chemokine (ctack) or vasoactive intestinal contractor (vic) chemokines |
| 07/06/2000 | CA2356608A1 A. fumigatus acetyl coenzyme-a carboxylase genes and polypeptides abd uses thereof |
| 07/06/2000 | CA2356606A1 Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356548A1 Human brainiac-5 |
| 07/06/2000 | CA2356475A1 Method for producing autogenous vaccines for treating chlamydial infections in mammals and humans |
| 07/06/2000 | CA2356462A1 Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356459A1 Method of using a matrix metalloproteinase inhibitor and radiation therapy as combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356402A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia |
| 07/06/2000 | CA2356302A1 Method of using a cyclooxygenase-2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia |
| 07/06/2000 | CA2356057A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 07/06/2000 | CA2355227A1 Targeted gene transfer using g protein coupled receptors |
| 07/06/2000 | CA2355096A1 Treatment and diagnosis of cancer using inositolphosphoglycans antagonists |
| 07/06/2000 | CA2354431A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 07/06/2000 | CA2334958A1 Peptide mimics useful for treating disease |